Tamsulosin for the treatment of benign prostatic hyperplasia

To investigate the efficacy and safety of Tamsulosin for benign prostatic hyperplasia (BPH), from July 1997 to Oct. 1997, 60 patients with symptomatic BPH were received tamsulosin 0.2mg daily for 6 weeks. The results showed that patients had a clinically significant response to the treatment of tamsulosin, and defined as those with 39.7% decrease in Ⅰ-PSS scores; 22.9% and 36% improvement in maximal urinary flow rate (MFR) and average urinary flow rate (AFR), respectively. Post-void residual urine (PVR) decreased in 51.6% ( P 0.01) in 47 patients. Tamsulosin had no significant effect on prostatic volume, blood pressure and pulse rate for all of the patients ( P 0.05 respectively). Mild adverse effects were noticed.